AIM
INFI

Acrospire Investment Management’s Infinity Pharmaceuticals, Inc. INFI Stock Holding History

Acrospire Investment Management’s Portfolio INFI Stock Details INFI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q1 		– Sell
-49,825
Closed -$67K – 2575
2016
Q4 		$67K Buy
+49,825
New +$65.1K 0.03% 1205

Other funds holding INFI

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
PA
Pinnacle Associates New York $9.16B AUM 63.5% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
PIM
Platinum Investment Management Sydney Australia 2000, Australia $397M AUM 63.96% 1-Year Est. Return

Acrospire Investment Management's INFI Position: Q1 2017 in Review

Acrospire Investment Management sold out of Infinity Pharmaceuticals, Inc. (INFI) in Q1 2017, closing a stake of 49,825 shares — an estimated $67K sold.

Acrospire Investment Management first reported a position in INFI in Q4 2016 and held it in 1 quarter. The position peaked at $67K in Q4 2016. 80 funds tracked by Wall St. Rank hold INFI as of Q1 2017.

  • Acrospire Investment Management reported no remaining Infinity Pharmaceuticals, Inc. position as of Q1 2017 after selling out during the quarter.
  • Acrospire Investment Management sold 49,825 Infinity Pharmaceuticals, Inc. shares in Q1 2017, an estimated $67K.
  • Acrospire Investment Management first reported a position in Infinity Pharmaceuticals, Inc. in Q4 2016 and held it in 1 quarter.
  • Acrospire Investment Management's Infinity Pharmaceuticals, Inc. position peaked at $67K in Q4 2016.
  • 80 funds tracked by Wall St. Rank held Infinity Pharmaceuticals, Inc. as of Q1 2017.

Based on Acrospire Investment Management's 13F filing for Q1 2017, filed 4 May 2017.